跳至主要内容
临床试验/ISRCTN04929580
ISRCTN04929580已完成不适用

In vivo changes in haemostasis after intravenous administration of plasma-derived factor VII and recombinant factor VII(a): a randomised controlled cross over multicentre intervention study

Radboud University Nijmegen Medical Center (Netherlands)0 个研究点目标入组 10 人开始时间: 2011年7月12日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Factor VII clotting activity of less than 5%
  • 2. Age 18 years or older
  • 3. Wash-out period of pdFVII or rFVII(a) of at least 3 days
  • 4. Male or female
  • 5. The intention to participate in a cross-over design (treated-twice)

排除标准

  • 1. Age < 18 years
  • 2. Known allergy to plasma proteins
  • 3. Bleeding episode resulting in a drop in haemoglobin (Hb) levels of >1 mmol/l (64.5 g/l), trauma or surgery in the last 6 weeks
  • 4. Fever (> 38 degrees centigrade)
  • 5. Clinical indication of liver cirrhosis (echographic indication, enlarged spleen, enlarged liver, decreased platelet count)
  • 6. Hepatitis C recently treated with interferon (wash-out 6 months)
  • 7. Human immunodeficiency virus (HIV) positive
  • 8. Pregnancy
  • 9. Medication:
  • 9.1. Non-steroid anti-inflammatory drugs (NSAIDs)
  • 9.2. Clopidogrel
  • 9.3. Antimicrobial medication
  • 9.4. Thyroid inhibitors
  • 9.5. Serotonin-specific reuptake inhibitor (SSRI?s)
  • 9.6. Hb levels < 7.5 mmol/l for women, < 8.4 mmol/l for men

研究者

发起方
Radboud University Nijmegen Medical Center (Netherlands)

相似试验